Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
Po-Ying Chan-Hui, Bellevue, WA (US); Steven Frey, Redmond, WA (US); Ole Olsen, Everett, WA (US); Jennifer Mitcham, Redmond, WA (US); Matthew Moyle, Redmond, WA (US); Sanjay K. Phogat, Frederick, MD (US); Dennis R. Burton, La Jolla, CA (US); Laura Marjorie Walker, San Diego, CA (US); Pascal Raymond Georges Poignard, San Diego, CA (US); Wayne Koff, Stony Brook, NY (US); Melissa Danielle De Jean De St. Marcel Simek-Lemos, Brooklyn, NY (US); and Stephen Kaminsky, Bronx, NY (US)
Assigned to Theraclone Sciences, Inc., Seattle, WA (US); International AIDS Vaccine Initiative, Inc., New York, NY (US); and The Scripps Research Institute., La Jolla, CA (US)
Filed by Theraclone Sciences, Inc., Seattle, WA (US); International AIDS Vaccine Initiative, Inc., New York, NY (US); and The Scripps Research Institute, La Jolla, CA (US)
Filed on Jun. 5, 2024, as Appl. No. 18/734,520.
Application 18/734,520 is a division of application No. 18/150,957, filed on Jan. 6, 2023, granted, now 12,018,067.
Application 18/150,957 is a continuation of application No. 17/082,322, filed on Oct. 28, 2020, granted, now 11,584,789, issued on Feb. 21, 2023.
Application 17/082,322 is a continuation of application No. 16/513,859, filed on Jul. 17, 2019, granted, now 10,865,234, issued on Dec. 15, 2020.
Application 16/513,859 is a continuation of application No. 16/275,936, filed on Feb. 14, 2019, granted, now 10,407,493, issued on Sep. 10, 2019.
Application 16/275,936 is a continuation of application No. 15/918,343, filed on Mar. 12, 2018, granted, now 10,239,934, issued on Mar. 26, 2019.
Application 15/918,343 is a continuation of application No. 14/692,483, filed on Apr. 21, 2015, granted, now 9,920,111, issued on Mar. 20, 2018.
Application 14/692,483 is a continuation of application No. 12/726,245, filed on Mar. 17, 2010, granted, now 9,051,362, issued on Jun. 9, 2015.
Claims priority of provisional application 61/285,664, filed on Dec. 11, 2009.
Claims priority of provisional application 61/224,739, filed on Jul. 10, 2009.
Claims priority of provisional application 61/165,829, filed on Apr. 1, 2009.
Claims priority of provisional application 61/161,010, filed on Mar. 17, 2009.
Prior Publication US 2024/0343782 A1, Oct. 17, 2024
1. An expression vector that encodes and stably expresses in vivo an antibody comprising (a) a light chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS: 120, 121, and 44, and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 116, 117, and 118.